Clinical Trial Update: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma [Phase 1]

View source ↗

Summary

A Phase I study evaluating oral topotecan as a radiosensitizer in patients with rectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Topotecan (topotecan)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Rectal Neoplasms | Phase 1 | Status: COMPLETED